Cytomegalovirus infection during renal transplantation
Renal transplantation (RT) is considered the best therapy for patients with chronic renal failure. Renal transplant patients have an elevated risk of infections, and viral diseases have a high prevalence, especially during the first year after RT. Viral infections might influence, in the short and long term, the graft outcome and the patient’s survival.
Cytomegalovirus (CMV) disease can be particularly dangerous in immunosuppressed patients and its evaluation is important in the follow-up of RT.
The aim of this review is to present a brief analysis of the epidemiology, clinic characteristics and methods currently available to the clinician for the diagnosis of CMV diseases. The impact, risk factors, main preventive and therapeutic measures currently available to manage CMV diseases in the early stages of RT will also be described, referring to the recent guidelines on the CMV management in transplanted patients.
KottonCKumarDCaliendoAMet al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation; Transplantation2018; 102:900–931.
2.
BeamERazonableRR.Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment. Curr Infect Dis Rep2012; 14(6):633–641.
3.
ZhangLJHanffPRutherfordCChurchillWHCrumpackerCS.Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. The J Infect Dis1995; 171(4):1002–1006.
4.
TandonRMocarskiES.Viral and host control of cytomegalovirus maturation. Trends Microbiol2012; 20(8):392–401.
5.
KuteVBVanikarAVShahPRet al. Post-renal transplant cytomegalovirus infection: study of risk factors. Transplant Proc2012; 44(3):706–709.
6.
LjungmanPBoeckhMHirschHHet al. Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis2017; 64(1): 87–91.
7.
HumarAMazzulliTMoussaGet al. Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High-risk CMV D+/R- Transplant Recipients. Am J Transplant2005; 5(5):1065–1070.
8.
TheTHvan der BijWvan den BergAPet al. Cytomegalovirus Antigenemia. Clin Infect Dis1990; 12(Supplement 7):S737–S744.
9.
RazonableRRPayaCVSmithTF.Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol2002; 40(3):746–52.
10.
ManuelOHusainSKumarDet al. Assessment of Cytomegalovirus-Specific Cell-Mediated Immunity for the Prediction of Cytomegalovirus Disease in High-Risk Solid-Organ Transplant Recipients: A Multicenter Cohort Study. Clin Infect Dis2013; 56(6):817–824.
11.
KumarDMianMSingerLHumarA.An Interventional Study Using Cell-Mediated Immunity to Personalize Therapy for Cytomegalovirus Infection After Transplantation. Am J Transplant2017; 17(9):2468–2473.
12.
KaruthuSBlumbergEA.Common infections in kidney transplant recipients. CJASN2012; 7(12):2058–2070.
13.
IssaNCFishmanJASnydmanDR.Infectious Complications of Antilymphocyte Therapies in Solid Organ Transplantation. Clin Infect Dis2009; 48(6):772–786.
14.
ReischigTJindraPSvecováMet al. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol2006; 36(2):146–151.
15.
HelanteräIKoskinenPFinnePet al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transplant International2006; 19(11):893–900.
16.
FlorescuDFAbu-ElmagdKMercerDFet al. An international survey of cytomegalovirus prevention and treatment practices in intestinal transplantation. Transplantation2014; 97(1):78–82.
17.
ValantineHALuikartHDoyleRet al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation2001; 72(10):1647–52.
18.
AsbergAHumarARollagHet al. VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant2007; 7(9):2106–2113.
19.
SiaIGWilsonJAGroettumCMet al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis2000; 181(2):717–720.
20.
SahooMKLefterovaMIYamamotoFet al. Detection of Cytomegalovirus Drug Resistance Mutations by Next-Generation Sequencing. J Clin Microbiol2013; 51(11):3700–3710.
21.
AndrassyJHoffmannVSRentschMet al. Is Cytomegalovirus Prophylaxis Dispensable in Patients Receiving an mTOR Inhibitor–Based Immunosuppression? A Systematic Review and Meta-Analysis. Transplantation Journal2012; 94(12):1208–1217.
